JPA: System, Multipurpose For In Vitro Coagulation Studies

Product code JPA, “System, Multipurpose For In Vitro Coagulation Studies” in FDA's classification database, is a Class II device type under 21 CFR 864.5425 (multipurpose system for in vitro coagulation studies), reviewed by FDA's Hematology panel. FDA's 510(k) database lists 181 clearances under JPA, 28 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
JPA
Regulation
21 CFR 864.5425
Class
II
Panel
Hematology
Clearances
181
Most recent
Apr 27, 2026
Median review, last 2 years
47 days
Third-party review
Eligible
Implant
No

What it covers

A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.

The identification in 21 CFR 864.5425, multipurpose system for in vitro coagulation studies. FDA gives JPA no definition of its own, so the regulation’s describes it.

Recent clearances

510(k)DeviceApplicantDecisionType
K253658STA Satellite Max®Diagnostica Stago, Inc.Apr 27, 2026Traditional
K250965Automated Blood Coagulation Analyzer CN-Series (CN-6000)Sysmex America, Inc.Jun 2, 2025Traditional
K251024TEG 6s Hemostasis System Citrated: K, KH, RT, FF Assay CartridgeHaemoneticsApr 30, 2025Special
K243858TEG 6s Hemostasis System Citrated: K, KH, RT, FF Assay CartridgeHaemonetics CorporationJan 15, 2025Special
K232018Citrated: K, KH, RTH, FFHHaemonetics CorporationMar 29, 2024Traditional
K233790ACL TOP 970 CLInstrumentation LaboratoryDec 29, 2023Special
K221359ACL TOP 970 CL, HemosIL CL Anti-Cardiolipin IgM, HemosIL CL Anti-ß2 Glycoprotein-I IgMInstrumentation Laboratory COSep 29, 2023Traditional
K212183STA R Max 3, STA Compact Max 3Diagnostica Stago S.A.SJun 7, 2023Traditional
K201440ROTEM sigma Thromboelastometry SystemTem Innovations GmbHJul 8, 2022Traditional
K202101GEM Hemochron 100 System, GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+), GEM Hemochron 100 Low Range Activated Clotting Time Test (ACT-LR), directCHECK ACT+ Whole Blood Control, Level 1 and Level 2, directCHECK ACT-LR Whole Blood Control, Level 1 and Level 2Accriva Diagnostics, Inc.Dec 29, 2021Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 181 with a free account)

Clearances by year

28 JPA 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)1158
2025330
20241266
20233506
20221767
20211518
20193175
20181219
20174117
20166114
2015299
2013129
20111433

Who submits

15 applicants cleared a JPA device since 2011. 46% of the clearances went to applicants in United States, then Germany (36%), France (7%) and Spain (4%). By type: Traditional 71% and Special 29%.

ApplicantClearances since 2011
Siemens Healthcare Diagnostics Products GmbH6
Haemonetics Corporation4
Accriva Diagnostics, Inc.2
Diagnostica Stago S.A.S2
Instrumentation Laboratory CO2
Siemens Healthcare Diagnostic Products GmbH2
Tem Innovations GmbH2
Coramed Technologies, LLC1

How FDA classifies it

Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.

From 21 CFR 864.5425. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 864.5425 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent JPA clearances declared.

Ask about JPA

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about JPA

What is FDA product code JPA?

Product code JPA, “System, Multipurpose For In Vitro Coagulation Studies” in FDA's classification database, is a Class II device type under 21 CFR 864.5425 (multipurpose system for in vitro coagulation studies), reviewed by FDA's Hematology panel. FDA's 510(k) database lists 181 clearances under JPA, 28 of them since 2011.

How many 510(k) clearances are there under JPA?

FDA’s 510(k) database listed 181 clearances under JPA as of Oct 29, 2026, 28 of them decided since 2011; the most recent decision was Apr 27, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a JPA 510(k)?

For the 4 JPA clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 47 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most JPA clearances?

Since 2011: Siemens Healthcare Diagnostics Products GmbH (6), Haemonetics Corporation (4), Accriva Diagnostics, Inc. (2), Diagnostica Stago S.A.S (2) and Instrumentation Laboratory CO (2). 15 applicants have cleared a JPA device in that time.

Sources

  1. FDA product classification: JPA · Product Classification database
  2. 21 CFR 864.5425: Multipurpose system for in vitro coagulation studies · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for JPA · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow JPAGet an email when FDA clears, recalls or publishes guidance for JPA devices.

Know what FDA already cleared.